Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744182 | 1.00 | GPR119 (0.47) | GPR119HRH3CHRM2CHRM1STS | |
| SCHEMBL24945645 | 0.89 | GPR119 (0.49) | GPR119PIK3CD | |
| SCHEMBL31027274 | 0.86 | CHRM2 (0.46) | GPR119CHRM2CHRM1 | |
| SCHEMBL23728096 | 0.86 | GPR119 (0.39) | GPR119HRH3CHRM2CHRM1 | |
| SCHEMBL26088649 | 0.86 | GPR119 (0.39) | GPR119HRH3CHRM2CHRM1 | |
| SCHEMBL23744252 | 0.85 | CHRM2 (0.50) | HRH3CHRM2CHRM1 | |
| SCHEMBL23744444 | 0.85 | CHRM2 (0.50) | HRH3CHRM2CHRM1 | |
| SCHEMBL23744202 | 0.85 | CHRM2 (0.48) | GPR119CHRM2CHRM1STS | |
| SCHEMBL23744255 | 0.83 | CHRM1 (0.48) | HRH3CHRM2CHRM1 | |
| SCHEMBL23744254 | 0.83 | CHRM1 (0.48) | HRH3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | GPR119 188/4885HRH3 104/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.